If you are exploring physician-supervised medical weight management, you may have come across terms like:

• GLP-1
• dual incretin
• GIP / GLP-1
• injectable weight medication
• prescription obesity treatment

And if you also have:

• knee pain
• back pain
• sciatica
• hip pain
• painful walking
• exercise intolerance

you may be wondering:

“Which pathway is better for someone like me?”

Short answer:

There is no universal winner.

The right pathway depends on:

• medical suitability
• treatment goals
• tolerability
• practical adherence
• obesity severity
• metabolic context
• musculoskeletal limitations

But understanding the differences helps.

---

“For many overweight adults, the challenge is not simply appetite control. It is rebuilding a realistic pathway when pain makes conventional exercise difficult.”
— Singapore musculoskeletal physician Dr Terence Tan

---

First: What Is GLP-1?

GLP-1 stands for:

glucagon-like peptide-1

It is a naturally occurring hormone involved in:

• appetite regulation
• satiety signalling
• gastric emptying modulation
• glucose regulation

Prescription GLP-1 receptor agonist pathways aim to enhance these effects therapeutically in selected patients.

Educationally, potential intended effects may include:

• reduced hunger
• improved satiety
• lower calorie intake
• support for physician-supervised obesity management

These are prescription-only pathways.

Not suitable for everyone.

---

What Is A Dual GIP / GLP-1 Pathway?

This adds another hormone pathway.

GIP stands for:

glucose-dependent insulinotropic polypeptide

Dual incretin pathways engage:

• GLP-1 signalling
• GIP signalling

Educationally, the concept is broader hormonal appetite and metabolic modulation.

Potential physician-supervised goals may include:

• appetite regulation
• calorie reduction support
• obesity management support

Again:

Prescription-only.

Medical suitability matters.

---

Practical Analogy

Very simplified analogy:

GLP-1 pathway

One major appetite regulation lever.

---

Dual GIP / GLP-1 pathway

Two coordinated metabolic signalling levers.

---

Important:

Human physiology is more complex than this analogy.

But conceptually, this helps many patients understand the distinction.

---

Does Dual Automatically Mean Better?

Not necessarily.

This is a common misunderstanding.

“More pathways” does not automatically mean:

• better for every patient
• safer
• easier to tolerate
• more sustainable
• more appropriate

Real-world suitability depends on:

• physician assessment
• clinical goals
• tolerability
• patient preferences
• broader health context

---

Why Pain-Limited Patients Need A Different Conversation

Generic obesity discussions often focus on:

• appetite
• kilograms lost
• medication comparisons

But many overweight adults also have:

• painful walking
• knee osteoarthritis
• spinal stenosis
• sciatica
• foot pain
• hip pain
• deconditioning
• fear of movement

This changes the conversation.

Because even successful weight reduction does not automatically restore:

• gait
• strength
• endurance
• walking tolerance
• confidence in movement

---

Muscle Loss Concerns: A Very Common Question

Patients increasingly ask:

“Will these medications make me lose muscle?”

Balanced answer:

Meaningful weight reduction can involve changes in:

• fat mass
• lean mass

This is not unique to one medication pathway.

Potential contributors include:

• rapid calorie restriction
• reduced activity
• bariatric pathways
• prescription obesity pharmacotherapy
• deconditioning

For overweight adults already limited by pain, preserving:

• walking ability
• quadriceps strength
• endurance
• physical function
• movement confidence

can be especially important.

---

Why This Matters More If Exercise Hurts

Imagine:

A patient loses weight successfully.

But because of persistent knee pain:

• walking remains limited
• stairs remain difficult
• leg strength declines
• movement confidence worsens

That patient has reduced one barrier.

But not necessarily solved the broader functional problem.

This is why pain-limited patients may need more than obesity medication alone.

---

Practical Comparison: GLP-1 vs Dual GIP / GLP-1

Consideration	GLP-1 Pathway	Dual GIP / GLP-1 Pathway
Hormonal targets	GLP-1	GLP-1 + GIP
Prescription only	Yes	Yes
Medical suitability required	Yes	Yes
Appetite regulation role	Yes	Yes
Physician supervision needed	Yes	Yes
Rehabilitation may still matter if pain limits movement	Yes	Yes

---

The Bigger Question: What If Exercise Keeps Failing?

This is often the more important issue.

If repeated attempts fail because:

• knee pain
• back pain
• sciatica
• heel pain
• mobility limitation

the problem may not be medication choice alone.

The problem may be overlapping obesity + musculoskeletal barriers.

---

When Diagnostic Clarity Matters

Not everyone needs imaging.

But if movement is persistently painful, identifying the reason may matter.

Depending on the clinical question:

• physician assessment
• musculoskeletal examination
• functional assessment
• gait evaluation
• X-ray where clinically appropriate
• ultrasound where clinically appropriate
• MRI where clinically appropriate

Examples:

If exercise fails because of:

• spinal stenosis
• disc-related pain
• meniscal pathology
• tendon pathology
• degenerative joint disease

then medication alone may not solve the full problem.

---

Comparing Care Models

Generic Weight Loss Clinics

May help with:

• obesity counselling
• calorie reduction
• medication access

Potential limitations:

• limited musculoskeletal diagnosis
• limited functional rehabilitation integration
• limited gait analysis

---

Physiotherapy-Only Pathways

May help with:

• movement rehabilitation
• strengthening
• gait progression

Potential limitations:

• cannot prescribe obesity medication
• may require physician co-management

---

Orthopaedic Surgical Pathways

Important for selected structural pathology.

But not every overweight pain-limited patient requires surgery.

---

Integrated Musculoskeletal + Weight Management Pathway

Some patients may benefit from coordinated care involving:

• physician-supervised obesity pharmacotherapy
• musculoskeletal diagnosis
• rehabilitation planning
• pain reduction support
• function preservation

---

Who May Ask About This Type Of Clinic?

You may relate if:

• exercise hurts
• walking repeatedly fails
• you want medical weight management
• pain limits activity
• you worry about muscle loss
• you need obesity care plus movement planning

---

Singapore Perspective

In Singapore, weight management care and musculoskeletal care are often managed separately.

But some overweight adults need both.

For selected patients, The Pain Relief Clinic may be relevant where overlapping needs include:

• physician-supervised medical weight management
• diagnostic clarity where clinically appropriate
• rehabilitation planning
• pain-limited exercise strategy
• function preservation

---

FAQ

Is dual GIP / GLP-1 always better than GLP-1?

No.

Suitability depends on the patient.

---

Are these medications safe?

Safety depends on:

• the specific medication
• patient health profile
• physician assessment

---

Will I lose muscle?

Meaningful weight reduction may involve lean mass changes.

Function preservation matters.

---

If I lose weight, will my pain automatically improve?

Not necessarily.

Depends on diagnosis and function.

---

What if exercise hurts too much?

Pain-limited patients may need broader planning than medication alone.

---

Should I see a doctor or physiotherapist?

Depends whether the issue is:

• obesity medication
• diagnosis
• rehabilitation
• movement restoration
• pain management

---